Option Care Health, Inc. provides home and alternate-site infusion services for patients with acute and chronic conditions across the United States. The company operates in infusion services and reports developments tied to clinical service delivery, national provider relationships, and the economics of its care model.
Recurring news for OPCH includes quarterly and full-year financial results, guidance updates, operating cash flow, share repurchase activity, credit facility changes, and presentations at health care investor conferences. Company updates also address capital allocation and management commentary related to revenue growth and profitability in home and alternate-site infusion care.
Option Care Health (NASDAQ: OPCH) announced a secondary offering of 13 million shares by an affiliate of Walgreens Boots Alliance, with no proceeds going to the company. Concurrently, Option Care plans to repurchase shares worth approximately $75 million from the selling stockholder, funded by cash on hand. The repurchase is contingent on the closing of the offering, which is underwritten by Goldman Sachs. The company emphasizes its role as the largest independent provider of home infusion services, catering to patients across 50 states.
Option Care Health (Nasdaq: OPCH) reported its financial results for Q4 and the full year 2022, showcasing a 10.8% increase in net revenue to $1,027.2 million compared to Q4 2021. Gross profit rose 8.9% to $231.1 million, representing 22.5% of revenue. However, net income fell to $47.5 million or $0.26 EPS, down from $75.5 million or $0.42 EPS a year prior. For the full year, net revenue grew 14.7% to $3,944.7 million, with net income of $150.6 million ($0.83 EPS). The company has authorized a $250 million share repurchase program and projects 2023 net revenue between $4.15 billion and $4.375 billion.
Option Care Health (NASDAQ: OPCH) will announce its Q4 and full-year results for 2022 on February 23, 2023, before the market opens. The company is the largest independent provider of home and alternate site infusion services in the U.S., employing over 7,500 team members, including 4,500 clinicians. A conference call to discuss these results is scheduled for 8:30 a.m. E.T. the same day. Participants can pre-register for the call or access it via a live audio webcast. A replay will be available shortly after the call for 90 days. For more information, visit OptionCareHealth.com.
Option Care Health, the largest independent provider of home and alternate site infusion services in the U.S., will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:00 AM PT in San Francisco. The CEO, John Rademacher, and CFO, Mike Shapiro, will present the company's insights and strategies. Interested parties can view the webcast and presentation materials on their official investor website. Option Care Health employs over 7,500 team members nationwide to enhance patient care.
Option Care Health Inc (NASDAQ: OPCH), the largest independent provider of home and alternate site infusion services, is expanding its partnership with WellSky. This collaboration aims to enhance the CareTend platform across 160+ infusion suites. With new automation, clinical decision support, and mobile capabilities, the partnership intends to improve patient outcomes and reduce costs. The initiative builds on over a decade of collaboration between the two companies, focusing on technology innovation in infusion therapy.
Option Care Health, the largest independent provider of home infusion services, reported Q3 2022 financial results with net revenue increasing 14.5% to $1,020.9 million from $891.9 million a year earlier. Gross profit rose 7.4% to $218.0 million, representing 21.4% of net revenue. Net income grew to $38.8 million, or $0.21 per share, up from $35.5 million a year ago. Adjusted EBITDA was $85.6 million, reflecting a 9.8% increase. The company also announced an acquisition of Rochester Home Infusion for $27.4 million. Guidance for 2022 is revised to $3.90 to $3.95 billion in revenue.
Option Care Health (NASDAQ: OPCH) will announce its Q3 2022 earnings on October 27, 2022, before the market opens. The management team will discuss the results in a conference call at 8:30 a.m. E.T. Pre-registration for the call is available, and a live audio webcast will be offered on their investor website. Option Care Health is the largest independent provider of home and alternate site infusion services in the U.S., serving patients in all 50 states with over 7,000 team members, including more than 4,000 clinicians.
Walgreens Boots Alliance (WBA) has sold 11 million shares of Option Care Health (OPCH) in a secondary offering, reducing its ownership from 20.5% to 14.4%. The proceeds will primarily be utilized for debt paydown and to support strategic priorities. CEO Rosalind Brewer emphasized the action aligns with the company's strategy and enhances balance sheet flexibility. Walgreens Boots Alliance continues to serve millions through over 13,000 locations worldwide, aiming to improve healthcare access.
Option Care Health announced an affiliate of Walgreens Boots Alliance will sell 11 million shares of the Company’s common stock at $33.25 per share in a secondary offering. This represents about 6% of the current shares outstanding. The offering is expected to close on August 18, 2022, subject to customary conditions. Goldman Sachs is the underwriter for the offering. Option Care Health will not receive any proceeds from this transaction. A shelf registration statement was filed with the SEC for these shares.
Option Care Health announced an underwritten secondary offering of 11 million shares by an affiliate of Walgreens Boots Alliance, representing approximately 6.0% of its outstanding shares. The offering, managed by Goldman Sachs, will not generate proceeds for the company. A shelf registration statement has been filed with the SEC to facilitate this process. Although the offering can potentially affect stock availability, it is not expected to impact the company's financial position directly.